Rocuronium
Uterine Neoplasms
Yuri Semenyuk Rivne Regional Clinical HospitalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Uterine Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FULVESTRANT Atavistik Bio, Inc | Phase 2 | B |
Hycamtin Montefiore Medical Center | Phase 2 | B |
Docetaxel Montefiore Medical Center | Phase 2 | B |
TRASTUZUMAB Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | CCC |
Tucatinib Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | CCC |
View all 12 →
Same molecule, other indications
Rocuronium is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →